摘要
目的研究小儿喘息性支气管炎应用小儿肺热咳喘颗粒口服联合布地奈德雾化吸入治疗的临床疗效及安全性.方法回顾分析安福县人民医院2019年3月-2021年3月收治的60例喘息性支气管炎患儿临床资料,按入院顺序将其分成两组,对照组(n=30例)采用布地奈德雾化吸入治疗,在此基础上,观察组(n=30例)联合小儿肺热咳喘颗粒治疗,对比两种治疗方式的差异性.结果治疗后,观察组临床总有效率(96.67%)明显高于对照组(73.33%),且不良反应发生率(6.67%)明显低于对照组(30.00%)(P<0.05);观察组发热、喘息、咳嗽和哮鸣音等临床症状及体征消失时间均低于对照组(P<0.05);观察组TV、TPTEF/TE均高于对照组(P<0.05);观察组RR、hs-CRP和IL-6均低于对照组(P<0.05).结论小儿喘息性支气管炎应用小儿肺热咳喘颗粒口服联合布地奈德雾化吸入治疗效果良好,可调节血清炎性因子水平,快速缓解临床症状改善患儿肺功能,且不良反应少,安全性高,值得临床应用.
Objective To study the clinical efficacy and safety of pediatric asthmatic bronchitis treated with oral administration of pediatric Feire Kechuan granule combined with budesonide atomization inhalation.Methods The clinical data of 60 children with asthmatic bronchitis treated in our hospital from March 2019 to March 2021 were retrospectively analyzed.They were divided into groups according to the admission order.The control group(n=30 cases)was treated with budesonide atomization inhalation.On this basis,the observation group(n=30 cases)was treated with children's Feire Kechuan granule,and the differences between the two treatment methods were compared.Resul ts After treatment,the total clinical effective rate of the observation group(96.67%)was significantly higher than that of the control group(73.33%),and the incidence of adverse reactions(6.67%)was significantly lower than that of the control group(30.00%)(P<0.05);the disappearance time of clinical symptoms and signs such as fever,wheezing,cough and wheezing in the observation group was lower than that in the control group(P<0.05);TV and TPTEF/TE in the observation group were higher than those in the control group(P<0.05);RR,hs CRP and IL-6 in the observation group were lower than those in the control group(P<0.05).Conc lus ion The application of Xiaoer Feire Kechuan granule combined with budesonide atomization inhalation in the treatment of asthmatic bronchitis in children has good effect.It can quickly alleviate clinical symptoms,regulate the level of serum inflammatory factors and improve children's lung function.It has less adverse reactions and high safety.It is worthy of clinical application.
作者
王俊青
Wang Junqing(Department of Pediatrics,Anfu county people's Hospital,Ji'an,Jiangxi 343200,China)
出处
《首都食品与医药》
2022年第18期135-137,共3页
Capital Food Medicine
